Showing 1141-1150 of 4012 results for "".
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
https://reachmd.com/clinical-practice/endocrinology/optimizing-patient-outcomes-in-ckd-t2d-care-with-confidence/36597/Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCEVedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.Burns Archive: A Behind-the-Scenes Look at Medical Photography Collection
https://reachmd.com/programs/clinicians-roundtable/burns-archive-behind-scenes-look-medical-photography-collection/9675/Stanley B. Burns, MD takes us through some of his favorite photos from his collection of over 1 million historic photographs.The History and Rationale of Cervical Cancer Screening Changes
https://reachmd.com/programs/clinicians-roundtable/history-rationale-cervical-cancer-screening-changes/7848/Standards in cervical cancer detection methods have come a long way in the past 30 years, from cervical cytology to HPV co-testing and HPV primary screening. How did the OB/GYN community get here, and is the direction of current practice standards in sync with clinical preferences nationwide? JoininHarnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
https://reachmd.com/programs/project-oncology/harnessing-the-immune-power-a-uniquely-designed-pd-1-inhibitor-for-esophageal-cancer/35512/Esophageal cancer is the tenth most common cancer worldwide and the sixth most prevalent cause of death due to cancer, which is why having additional treatment options for this disease is crucial.1 One available option, tislelizumab plus platinum-based chemotherapy, was recently approved by the FDAFrom Diagnosis to Prognosis: Using MyPath® Melanoma and DecisionDx®-Melanoma to Help Guide Patient Management Decisions
https://reachmd.com/programs/practical-dermatology/from-diagnosis-to-prognosis-using-mypath-melanoma-and-decisiondx-melanoma-to-help-guide-patient-management-decisions/39944/Gene Expression Profile Testing Helps Clinicians Clarify Diagnostically Ambiguous Lesions and Deliver Personalized, Risk-Aligned Melanoma CareShared Decision-Making in Pulmonary Arterial Hypertension: Strategies for PAH Treatment Initiation and Support
https://reachmd.com/programs/medical-industry-feature/shared-decision-making-in-pah-treatment-initiation/36303/Early diagnosis and intervention are critical for improving outcomes for patients with pulmonary arterial hypertension (PAH).1,2 Evidence-based guidelines recommend adding UPTRAVI® (selexipag)—a prostacyclin receptor agonist—at first follow-up for appropriate patients presenting at intermediate-lowCutera’s AviClear
https://reachmd.com/topics/energy-based-devices/cuteras-aviclear/35163/Visible Benefit of Compression for Leukocytoclastic Vasculitis
https://reachmd.com/programs/practical-dermatology/visible-benefit-of-compression-for-leukocytoclastic-vasculitis/24212/The use of compression stockings has been suggested in the management of leukocytoclastic vasculitis (LCV), however there are a lack of studies in the literature that provide evidence of the benefit of compression therapy in the treatment of LCV.1,2 Here we present a case that visually demonstratesNicotinamide for COVID-19 Recovery: Restoring Metabolic Balance
https://reachmd.com/programs/clinicians-roundtable/nicotinamide-for-covid-19-recovery-restoring-metabolic-balance/36410/